Tag Archives | 2018

Population pharmacokinetics of gentamicin in paediatrics: quantifying covariate-parameter relationship using the full random effects modelling (FREM) approach

Objectives: To (i) evaluate the suitability of a previous published population pharmacokinetic (PK) model of gentamicin in paediatric oncology patients1 in predicting drug exposure in non-oncology paediatric patients and (ii) investigate the relationship between PK parameters and covariates in both oncology and non-oncology paediatric patients using the full random-effect (FREM) covariate modelling approach.2 Methods: Data […]

Continue Reading

Assessing the completeness of a QSP model for azathioprine metabolism

Introduction: A QSP model for azathioprine metabolism was developed from known mechanistic pathways and expert opinion. The model was intended to predict the concentrations of 6-thioguanine nucleotides (TGN) and 6-methyl mercaptopurine (MMP) under different clinical scenarios [1-3]. The model was able to predict 6-TGN and 6-MMP for typical individuals but it was unable to predict […]

Continue Reading

Alphaxalone Anaesthesia PKPD

Background  Alphaxalone is an intravenous anaesthetic that has been formulated for human use as Phaxan™, an aqueous solution of alphaxalone 10 mg mL-1 and 13% betadex.  This study assessed the pharmacokinetic-pharmacodynamic (PKPD) characteristics of alphaxalone (Phaxan™) in humans. Methods: Alphaxalone 0.5 (0.42-0.55) [mean (range); mg kg-1] was given by single intravenous bolus injection of Phaxan™ to […]

Continue Reading

An approach to evaluating mass and energy balance of pharmacokinetic systems using bond graph theory

Introduction: Quantitative systems pharmacology models are used in PKPD and pharmacometrics to describe the effects of drugs as modulators of system behaviour.  In most cases the systems that are described in these models can be constructed of modular units that can be assembled en-masse to create the overall system.  An example of a modular component […]

Continue Reading

Linearisation and automatic scale reduction of bone biology QSP models for data-driven analyses

Background: Bone biology is physiologically complex. Peterson et al [1] developed a QSP model consisting of 28 states that links integrated calcium homeostasis, hormonal control mechanisms and bone remodelling which consists of two continuous processes, (i) bone resorption coordinated by osteoclasts, and (ii) bone formation by osteoblasts. While the model naturally accommodates homeostatic mechanisms it […]

Continue Reading

Kinetic modelling of ligand mediated internalisation

Introduction: Internalisation is by its nature kinetic.  Hence, application of the standard assumption of equilibrium conditions used by pharmacologists to determine the equilibrium constant (KD) is not obvious for either the ligand-mediated internalisation pathway or other functional assays that occur over the same timeframe as internalisation.  However, it is also difficult or impossible to estimate […]

Continue Reading

Evaluation of assumptions underpinning pharmacometric models

Background: All models are underpinned by assumptions. The validity of any inference drawn from a model depends on the appropriateness and likely impact of the underlying assumptions [1]. However, in the literature surrounding quantitative pharmacology models and pharmacometrics, assumptions inherent to model development and use are not routinely acknowledged, described, or evaluated. This casts doubt […]

Continue Reading

A population pharmacokinetic model for 51Cr EDTA to estimate renal function

Background 51Cr EDTA is a radioisotope used to estimate glomerular filtration rate (GFR), particularly in patients receiving renally cleared anticancer agents such as carboplatin. We propose that current methods for determining 51Cr EDTA clearance from plasma radioactivity (counts/minute) result in biased estimates of GFR. The aims of the study were (i) to develop and test […]

Continue Reading

Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma

Introduction. The combination of a BRAF inhibitor, dabrafenib and a MEK inhibitor, trametinib (CombiDT) has improved survival outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma. However, the use of CombiDT has a high incidence of pyrexia, causing treatment delays (Menzies, 2015). The pharmacokinetics and metabolism of dabrafenib and trametinib may […]

Continue Reading

ANZDATA: Pharmacology based time to event analysis for death and renal transplant failure

Background: The ANZDATA registry (http://www.anzdata.org.au/v1) has collected data on all patients receiving a renal transplant in Australia or New Zealand since 1977  Objective: To describe the effect of immunosuppressant medicines on time to death and time to renal transplant failure Methods: Demographic data and the daily dose of medicines used as immunosuppressants were extracted from […]

Continue Reading